Biostem Technologies (BSEM) Expected to Release Quarterly Earnings on Thursday

Biostem Technologies (NASDAQ:BSEM) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Biostem Technologies to post earnings of ($0.43) per share and revenue of $7.17 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Biostem Technologies (NASDAQ:BSEM) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The company had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $6.35 million. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%. On average, analysts expect Biostem Technologies to post ($1.90) EPS for the current fiscal year and ($1.04) EPS for the next fiscal year.

Biostem Technologies Stock Performance

BSEM opened at $1.15 on Thursday. The stock has a 50-day moving average of $2.93 and a 200 day moving average of $4.15. Biostem Technologies has a 12 month low of $1.04 and a 12 month high of $8.40. The firm has a market cap of $21.47 million, a P/E ratio of -0.72 and a beta of 0.36.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings began coverage on Biostem Technologies in a research note on Wednesday, August 19th. They issued a “sell (d-)” rating for the company. Wall Street Zen upgraded Biostem Technologies to a “sell” rating in a report on Saturday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.00.

About Biostem Technologies

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.